Sandoz marks 20 years of Omnitrope as biosimilar savings set stage for “golden decade”

Sandoz Group Ltd ( (CH:SDZ) ) has shared an update.

Sandoz is marking 20 years since the European approval of Omnitrope, the world’s first biosimilar, underscoring its pioneering role in establishing the biosimilar industry and strengthening its leadership in somatropin. The company highlights that Omnitrope alone has delivered more than USD 1.9 billion in savings and over 118 million patient treatment days in Europe, while biosimilars overall have generated EUR 56 billion in savings and nearly seven billion treatment days across the region.

Management frames this anniversary against an upcoming “golden decade” in which biologics worth around USD 320 billion will lose patent protection, presenting a major growth and access opportunity for Sandoz and healthcare systems. Alongside celebrating its biosimilar milestone, Sandoz points to 140 years of corporate heritage and 80 years of antibiotics manufacturing, positioning its expanding biosimilar portfolio and pipeline as central to future cost containment and broader access to advanced biologic therapies worldwide.

The most recent analyst rating on (CH:SDZ) stock is a Hold with a CHF75.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.

More about Sandoz Group Ltd

Sandoz Group AG is a Basel-based global leader in affordable medicines, focusing on generics and biosimilars that broaden patient access to treatments from common conditions to cancer. With a portfolio of about 1,300 medicines and 13 biosimilars, it serves over a billion patients worldwide and generated USD 11.1 billion in net sales in 2025, cementing its role as a key player in cost-effective healthcare.

YTD Price Performance: 15.18%

Average Trading Volume: 832,739

Technical Sentiment Signal: Buy

Current Market Cap: CHF29.31B

See more data about SDZ stock on TipRanks’ Stock Analysis page.